Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
CRANBURY, N.J., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will present at the Credit Suisse...
-
CRANBURY, N.J., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, November 5, 2020...
-
CRANBURY, N.J., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced additional positive interim results from its CLN6 Batten disease gene therapy program,...
-
CRANBURY, N.J., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel...
-
CRANBURY, N.J., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in upcoming presentations at...
-
Galafold 2Q2020 Revenue of $62.4 Million, On-Track to Achieve 2020 Revenue Guidance of $250M-$260M AT-GAA Phase 3 PROPEL Study Readout and Rolling BLA Submission to U.S. FDA on Schedule Advancing...
-
CRANBURY, N.J., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the BTIG...
-
CRANBURY, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, August 10, 2020 at...
-
$400M Debt Facility Provides Path to Profitability Without the Need for Any Future Dilutive Financings Self-sustainable Financial Profile Achieved with Comprehensive, Low Cost Debt Structure and...
-
CRANBURY, N.J., June 04, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will participate in a fireside chat...